Latest News
Corporate News
31.01.2023 | EQS-News
APONTIS PHARMA extends portfolio for the treatment of hypertension and hyperlipidemia by...
EQS-News: APONTIS PHARMA AG/ Key word(s): Product Launch APONTIS PHARMA extends portfolio for the treatment of...
Corporate News
29.11.2022 | EQS-News
APONTIS PHARMA: Number of announced market launches increases to ten Single Pills – Portfolio grows...
EQS-News: APONTIS PHARMA AG/ Key word(s): Product Launch APONTIS PHARMA: Number of announced market launches...
Corporate News
10.11.2022 | EQS-News
APONTIS PHARMA confirms 2022 forecast after successful nine-month period – Strong Single Pill...
EQS-News: APONTIS PHARMA AG/ Key word(s): 9 Month figures/Quarterly/ Interim Statement APONTIS PHARMA confirms 2022...
Corporate News
20.09.2022 | EQS-News
APONTIS PHARMA announces cooperation to launch new Single Pill in Germany
EQS-News: APONTIS PHARMA AG/ Key word(s): Alliance/Product Launch APONTIS PHARMA announces cooperation to launch new...
Corporate News
01.09.2022 | DGAP-News
APONTIS PHARMA: SECURE study and START study add-on analysis confirm superior efficacy of Single Pill
DGAP-News: APONTIS PHARMA AG/ Key word(s): Scientific publication APONTIS PHARMA: SECURE study and START study...
Corporate News
11.08.2022 | DGAP-News
APONTIS PHARMA expands profitable positioning in first half of 2022 – full-year forecast confirmed
DGAP-News: APONTIS PHARMA AG/ Key word(s): Half Year Report/Half Year Results APONTIS PHARMA expands profitable...
Corporate News
19.07.2022 | DGAP-News
APONTIS PHARMA and Midas Pharma agree on further development partnership for the market launch of a...
DGAP-News: APONTIS PHARMA AG/ Key word(s): Alliance/Market launch APONTIS PHARMA and Midas Pharma agree on further...
Corporate News
06.07.2022 | DGAP-News
APONTIS PHARMA rolls out new Single Pill for secondary prophylaxis
DGAP-News: APONTIS PHARMA AG/ Key word(s): Market launch APONTIS PHARMA rolls out new Single Pill for secondary...